GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sophiris Bio Inc (OTCPK:SPHS) » Definitions » EV-to-EBIT

Sophiris Bio (Sophiris Bio) EV-to-EBIT : 0.00 (As of May. 06, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Sophiris Bio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sophiris Bio's Enterprise Value is $0.00 Mil. Sophiris Bio's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 was $0.68 Mil. Therefore, Sophiris Bio's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for Sophiris Bio's EV-to-EBIT or its related term are showing as below:

SPHS's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 8.915
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Sophiris Bio's Enterprise Value for the quarter that ended in Sep. 2019 was $19.34 Mil. Sophiris Bio's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 was $0.68 Mil. Sophiris Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2019 was 3.53%.


Sophiris Bio EV-to-EBIT Historical Data

The historical data trend for Sophiris Bio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophiris Bio EV-to-EBIT Chart

Sophiris Bio Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 -2.05 -5.12 -4.20 -3.21

Sophiris Bio Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.89 -3.21 -5.48 -21.73 28.36

Competitive Comparison of Sophiris Bio's EV-to-EBIT

For the Biotechnology subindustry, Sophiris Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sophiris Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sophiris Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sophiris Bio's EV-to-EBIT falls into.



Sophiris Bio EV-to-EBIT Calculation

Sophiris Bio's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/0.682
=0.00

Sophiris Bio's current Enterprise Value is $0.00 Mil.
Sophiris Bio's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sophiris Bio  (OTCPK:SPHS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sophiris Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2019 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2019 ) =EBIT / Enterprise Value (Q: Sep. 2019 )
=0.682/19.342539
=3.53 %

Sophiris Bio's Enterprise Value for the quarter that ended in Sep. 2019 was $19.34 Mil.
Sophiris Bio's EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sophiris Bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sophiris Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sophiris Bio (Sophiris Bio) Business Description

Traded in Other Exchanges
N/A
Address
1258 Prospect Street, La Jolla, CA, USA, 92037
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is a genetically modified recombinant protein which is selectively activated by enzymatically active prostate-specific antigen (PSA), which is only present in the prostate, leading to localized cell death and tissue disruption without damage to neighboring tissue and nerves. Geographically all the operations of the company are functioned in the United States.
Executives
Randall E Woods director, officer: President & Chief Exec Officer C/O ARENA PHARMACEUTICALS, INC. 6166 NANCY RIDGE DRIVE SAN DIEGO CA 92121
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
James L Heppell director
Gerald T Proehl director
John Geltosky director 685 ROUTE 202/206, BRIDGEWATER NJ 08807
Joseph L Turner director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Joseph Lewis 10 percent owner PO BOX N7776, LYFORD BAHAMAS
Boxer Asset Management Inc. 10 percent owner CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Boxer Capital, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Mva Investors, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
William R Rohn director PO BOX 676367, RANCHO SANTA FE CA 92067